Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28(12):3301–14.
2.Oh HJ, Ryu KH, Park BJ, Yoon BH. Osteoporosis and osteoporotic fractures in gastrointestinal disease. J Bone Metab. 2018;25(4):213–7.
PubMed PubMed Central Google Scholar
3.Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, et al. The impact of inflammatory bowel disease in Canada 2018: extra-intestinal diseases in IBD. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S73–80.
4.Chedid VG, Kane SV. Bone health in patients with inflammatory bowel diseases. J Clin Densitom. 2019.
5.Gastroenterology BSo, Lewis N, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease: British society of Gastroenterology; 2008.
6.Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112(2):241–58.
7.Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54.
8.Adriani A, Pantaleoni S, Luchino M, Ribaldone DG, Reggiani S, Sapone N, et al. Osteopenia and osteoporosis in patients with new diagnosis of inflammatory bowel disease. Panminerva Med. 2014;56(2):145–9.
9.Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int. 2018;29(11):2389–97.
10.Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599–604.
PubMed PubMed Central Google Scholar
11.Schule S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, et al. Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterol J. 2016;4(5):669–76.
PubMed PubMed Central Google Scholar
12.Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107(4):1031–9.
13.Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med. 2000;133(10):795–9.
14.Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53(2):251–5.
CAS PubMed PubMed Central Google Scholar
15.van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology. 2003;125:15917.
16.Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology. 2002;123(2):468–75.
17.Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med. 2004;95(6):469–80.
18.Ludvigsson JF, Mahl M, Sachs MC, Bjork J, Michaelsson K, Ekbom A, et al. Fracture risk in patients with inflammatory bowel disease: a Nationwide population-based cohort study from 1964 to 2014. Am J Gastroenterol. 2019;114(2):291–304.
19.Even Dar R, Mazor Y, Karban A, Ish-Shalom S, Segal E. Risk factors for low bone density in inflammatory bowel disease: use of glucocorticoids, low body mass index, and smoking. Dig Dis. 2019;37(4):284–90.
20.van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl. 2006:59–64.
21.Gupta S, Wu X, Moore T, Shen B. Frequency, risk factors, and adverse sequelae of bone loss in patients with ostomy for inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20(2):259–64.
22.Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13(3):259–65.
23.Naito T, Yokoyama N, Kakuta Y, Ueno K, Kawai Y, Onodera M, et al. Clinical and genetic risk factors for decreased bone mineral density in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2018;33(11):1873–81.
24.Adamopoulos IE. Inflammation in bone physiology and pathology. Curr Opin Rheumatol. 2018;30(1):59–64.
CAS PubMed PubMed Central Google Scholar
25.Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57(5):684–94.
26.Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology. 2000;119(4):909–20.
27.Cleynen I, Gonzalez JR, Figueroa C, Franke A, McGovern D, Bortlik M, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European project. Gut. 2013;62(11):1556–65.
28.Brinar M, Vermeire S, Cleynen I, Lemmens B, Sagaert X, Henckaerts L, et al. Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients. J Crohns Colitis. 2012;6(1):43–50.
29.Schulte C, Goebell H, Roher HD, Schulte KM. Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci. 2001;46(11):2521–8.
30.Krela-Kazmierczak I, Kaczmarek-Rys M, Szymczak A, Michalak M, Skrzypczak-Zielinska M, Drweska-Matelska N, et al. Bone metabolism and the c.-223C > T polymorphism in the 5'UTR region of the Osteoprotegerin gene in patients with inflammatory bowel disease. Calcif Tissue Int. 2016;99(6):616–24.
CAS PubMed PubMed Central Google Scholar
31.Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599–603.
32.Szymczak-Tomczak A, Krela-Kazmierczak I, Kaczmarek-Rys M, Hryhorowicz S, Stawczyk-Eder K, Szalata M, et al. Vitamin D receptor (VDR) TaqI polymorphism, vitamin D and bone mineral density in patients with inflammatory bowel diseases. Adv Clin Exp Med. 2019;28:975–80.
33.Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther. 1998;12(1):21–5.
34.Miznerova E, Hlavaty T, Koller T, Toth J, Holociova K, Huorka M, et al. The prevalence and risk factors for osteoporosis in patients with inflammatory bowel disease. Bratisl Lek Listy. 2013;114(8):439–45.
35.Lee S, Metcalfe A, Raman M, Leung Y, Aghajafari F, Letourneau N, et al. Pregnant women with inflammatory bowel disease are at increased risk of vitamin D insufficiency: a cross-sectional study. J Crohns Colitis. 2018;12(6):702–9.
PubMed PubMed Central Google Scholar
36.Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60(7):889–96.
37.Nielsen OH, Rejnmark L, Moss AC. Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis. 2018;12(6):742–52.
38.Limketkai BN, Mullin GE, Limsui D, Parian AM. Role of vitamin D in inflammatory bowel disease. Nutr Clin Pract. 2017;32(3):337–45.
39.Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35(3):308–16.
40.Rodriguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007;13(46):6156–65.
CAS PubMed PubMed Central Google Scholar
41.Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379(26):2547–56.
42.Sylvester FA. Inflammatory bowel disease: effects on bone and mechanisms. Adv Exp Med Biol. 2017;1033:133–50.
43.Maldonado-Perez MB, Castro-Laria L, Caunedo-Alvarez A, Montoya-Garcia MJ, Giner-Garcia M, Arguelles-Arias F, et al. Does the antitumor necrosis factor-alpha therapy decrease the vertebral fractures occurrence in inflammatory bowel disease? J Clin Densitom. 2019;22(2):195–202.
44.Castro B, Rivero M, Crespo J, Riancho JA, Valero C. Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease. Eur J Intern Med. 2017;39:e33–e4.
45.Hakimian S, Kheder J, Arum S, Cave DR, Hyatt B. Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors. Scand J Gastroenterol. 2018;53(2):168–72.
46.Veerappan SG, O'Morain CA, Daly JS, Ryan BM. Review article: the effects of antitumour necrosis factor-alpha on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(12):1261–72.
47.Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther. 2004;20(6):607–14.
留言 (0)